{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:52:49Z","timestamp":1781603569883,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,2,15]],"date-time":"2015-02-15T00:00:00Z","timestamp":1423958400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s00520-015-2625-9","type":"journal-article","created":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T10:31:34Z","timestamp":1424169094000},"page":"2649-2654","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines"],"prefix":"10.1007","volume":"23","author":[{"given":"Aung","family":"Naing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maen","family":"Abdelrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wheler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Janku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald S.","family":"Falchook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson","family":"Ilustre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengying","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,15]]},"reference":[{"key":"2625_CR1","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","volume":"156","author":"DB Allison","year":"1999","unstructured":"Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686\u201396","journal-title":"Am J Psychiatry"},{"key":"2625_CR2","first-page":"7","volume":"10","author":"CM Beasley Jr","year":"1997","unstructured":"Beasley CM Jr, Tollefson GD, Tran PV (1997) Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry 10:7\u201312","journal-title":"J Clin Psychiatry"},{"key":"2625_CR3","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.1158\/1078-0432.CCR-08-1247","volume":"14","author":"F Braiteh","year":"2008","unstructured":"Braiteh F, Soriano AO, Garcia-Manero G, Hong D, Johnson MM, Silvalde P, Yang H, Alexander S, Wolff J, Kurzrock R (2008) Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res 14:6296\u2013301","journal-title":"Clin Cancer Res"},{"key":"2625_CR4","doi-asserted-by":"crossref","first-page":"287457","DOI":"10.1155\/2012\/287457","volume":"2012","author":"DR Engineer","year":"2012","unstructured":"Engineer DR, Garcia JM (2012) Leptin in anorexia and cachexia syndrome. Int J Pept 2012:287457","journal-title":"Int J Pept"},{"key":"2625_CR5","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, Macdonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12:489\u201395","journal-title":"Lancet Oncol"},{"issue":"Suppl 21","key":"2625_CR6","first-page":"20","volume":"60","author":"R Ganguli","year":"1999","unstructured":"Ganguli R (1999) Weight gain associated with antipsychotic drugs. J Clin Psychiatry 60(Suppl 21):20\u20134","journal-title":"J Clin Psychiatry"},{"key":"2625_CR7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00004714-199906000-00014","volume":"19","author":"S Gupta","year":"1999","unstructured":"Gupta S, Droney T, Al-Samarrai S, Keller P, Frank B (1999) Olanzapine: weight gain and therapeutic efficacy. J Clin Psychopharmacol 19:273\u20135","journal-title":"J Clin Psychopharmacol"},{"key":"2625_CR8","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1093\/ajcn\/34.10.2013","volume":"34","author":"KB Harvey","year":"1981","unstructured":"Harvey KB, Moldawer LL, Bistrian BR, Blackburn GL (1981) Biological measures for the formulation of a hospital prognostic index. Am J Clin Nutr 34:2013\u20132022","journal-title":"Am J Clin Nutr"},{"key":"2625_CR9","unstructured":"Institute NC (2009) Common terminology criteria for adverse events v4.0 In Edition 2009"},{"key":"2625_CR10","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4088\/JCP.v62n0204","volume":"62","author":"BJ Kinon","year":"2001","unstructured":"Kinon BJ, Basson BR, Gilmore JA, Tollefson GD (2001) Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 62:92\u2013100","journal-title":"J Clin Psychiatry"},{"key":"2625_CR11","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1176\/ajp.156.2.312","volume":"156","author":"T Kraus","year":"1999","unstructured":"Kraus T, Haack M, Schuld A, Hinze-Selch D, Kuhn M, Uhr M, Pollmacher T (1999) Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 156:312\u20134","journal-title":"Am J Psychiatry"},{"key":"2625_CR12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0753-3322(01)00140-8","volume":"55","author":"R Kurzrock","year":"2001","unstructured":"Kurzrock R (2001) Cytokine deregulation in cancer. Biomed Pharmacother 55:543\u20137","journal-title":"Biomed Pharmacother"},{"key":"2625_CR13","doi-asserted-by":"crossref","first-page":"742","DOI":"10.4088\/JCP.v61n1006","volume":"61","author":"KI Melkersson","year":"2000","unstructured":"Melkersson KI, Hulting AL, Brismar KE (2000) Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 61:742\u20139","journal-title":"J Clin Psychiatry"},{"key":"2625_CR14","doi-asserted-by":"crossref","first-page":"e29330","DOI":"10.1371\/journal.pone.0029330","volume":"7","author":"HA Parsons","year":"2012","unstructured":"Parsons HA, Baracos VE, Dhillon N, Hong DS, Kurzrock R (2012) Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. PLoS One 7:e29330","journal-title":"PLoS One"},{"key":"2625_CR15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1055\/s-0031-1280793","volume":"44","author":"NR Raposo","year":"2011","unstructured":"Raposo NR, Ferreira AS, Gattaz WF (2011) Body mass index increase, serum leptin, adiponectin, neuropeptide Y and lipid levels during treatment with olanzapine and haloperidol. Pharmacopsychiatry 44:169\u201372","journal-title":"Pharmacopsychiatry"},{"key":"2625_CR16","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/schbul\/sbm141","volume":"34","author":"O Sentissi","year":"2008","unstructured":"Sentissi O, Epelbaum J, Olie JP, Poirier MF (2008) Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr Bull 34:1189\u201399","journal-title":"Schizophr Bull"},{"key":"2625_CR17","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1200\/JCO.1995.13.3.575","volume":"13","author":"JF Seymour","year":"1995","unstructured":"Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R (1995) Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 13:575\u201382","journal-title":"J Clin Oncol"},{"key":"2625_CR18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0002-9343(96)00352-X","volume":"102","author":"JF Seymour","year":"1997","unstructured":"Seymour JF, Talpaz M, Hagemeister FB, Cabanillas F, Kurzrock R (1997) Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin\u2019s disease. Am J Med 102:21\u20138","journal-title":"Am J Med"},{"key":"2625_CR19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/gut.2004.053330","volume":"54","author":"M Stroud","year":"2005","unstructured":"Stroud M (2005) Thalidomide and cancer cachexia: old problem, new hope? Gut 54:447\u20138","journal-title":"Gut"},{"key":"2625_CR20","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s13539-013-0113-y","volume":"4","author":"H Veasey-Rodrigues","year":"2013","unstructured":"Veasey-Rodrigues H, Parsons HA, Janku F, Naing A, Wheler JJ, Tsimberidou AM, Kurzrock R (2013) A pilot study of temsirolimus and body composition. J Cachex Sarcopenia Muscle 4:259\u201365","journal-title":"J Cachex Sarcopenia Muscle"},{"key":"2625_CR21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/WNF.0b013e3181fa2a6f","volume":"33","author":"G Venkatasubramanian","year":"2010","unstructured":"Venkatasubramanian G, Chittiprol S, Neelakantachar N, Shetty TK, Gangadhar BN (2010) A longitudinal study on the impact of antipsychotic treatment on serum leptin in schizophrenia. Clin Neuropharmacol 33:288\u201392","journal-title":"Clin Neuropharmacol"},{"key":"2625_CR22","first-page":"1427","volume":"19","author":"GJ Zhang","year":"1999","unstructured":"Zhang GJ, Adachi I (1999) Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 19:1427\u201332","journal-title":"Anticancer Res"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-015-2625-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-015-2625-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-015-2625-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,6]],"date-time":"2023-08-06T01:51:50Z","timestamp":1691286710000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-015-2625-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,15]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["2625"],"URL":"https:\/\/doi.org\/10.1007\/s00520-015-2625-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,15]]}}}